Anemia and renal dysfunction are the most frequent comorbidities in patients with chronic heart failure, who have negative impact on prognosis. The etiology of anemia of chronic heart failure and chronic kidney disease is multifactorial and includes iron metabolic disturbances of functional and/or absolute character. Optimization of antianemic therapy of patients with chronic heart failure and chronic kidney disease provides an individual approach to the antianemic medicine appointment by developing predictors of therapeutic correction effectiveness.
Purpose — to determine criteria for antianemic therapy effectiveness in patients with chronic heart failure and chronic kidney disease with anemia as for Fe II by examining the significance of predictive parameters of iron metabolism — hepcidin, soluble transferrin receptor, ferritin, transferrin, serum iron and total iron capacity of serum.
The study involved 70 patients with chronic heart failure II–IV functional class due to ischemic heart disease and chronic kidney disease stage II–III with anemia. The level of Hb was in the range of 82–93 g/l. Concentration of hepcidin, soluble transferrin receptor, ferritin, transferrin was determined by enzyme immunoassay. Most informative quality detected in the central regulator of iron metabolism — hepcidin and indicator of erythropoiesis activity — soluble transferrin receptor, which makes determining the appropriateness of these markers in health care with the aim of stratification of therapeutic mode effectiveness.